Wiluna Mining (Ticker: WMC AU) is a gold mining company that owns the Wiluna gold mining operation. The site has an existing process plant with capacity of 2.1 million tonnes per year and a flotation concentrator rated at 750,000 tonnes per year. Wiluna Mining plans a phased restart program that includes underground and surface exploration.

The offering was priced at AUD 0.65 per share and comprises 277 million shares. The base offering represents gross proceeds of AUD 180.05 million, approximately $125.33 million. Wiluna Mining is expected to begin trading on the ASX on October 22, 2026. Its stated IPO market capitalization is AUD 472.00 million, approximately $328.56 million.

Barrenjoey Markets and Argonaut Securities are joint lead managers, with Commonwealth Securities as co-manager.

Elice Group (Ticker: 0158S0 KS) is a South Korean provider of AI infrastructure, GPU cloud services and enterprise AI solutions. Founded in 2015 as a coding education platform, the company has expanded into modular AI data centres and proprietary cloud software designed to improve GPU utilisation. AI cloud accounted for 76% of revenue in 1H26, up from 7% in 2023.

Elice Group expects to begin trading on Korea Exchange (KOSDAQ) on October 20, 2026. The offering comprises 2,222,000 newly issued shares and was priced at KRW 90,500 per share, at the top of the indicative range of KRW 70,400–90,500. The offering represents KRW 201.09 billion in gross proceeds, or approximately $149.51 million, implying a market capitalisation of around KRW 1.01 trillion. Institutional bookbuilding was 388.8 times subscribed. Mirae Asset Securities is the lead manager, and Samsung Securities is the joint lead manager.

The company reported 1H26 revenue of KRW 34.4 billion and operating profit of KRW 10.3 billion, compared with FY25 revenue of KRW 39.5 billion. IPO proceeds will fund AI data-centre expansion and international growth. Key risks include capital-intensive infrastructure investment and reliance on public-sector contracts.

City Therapeutics (Ticker: CTY US) is a United States clinical biotech company developing RNA interference (RNAi) therapeutics to silence disease-relevant proteins. Its programs focus on thromboembolic diseases, Type 1 Stargardt disease, and anemia associated with chronic disease.

City Therapeutics expects to list on NASDAQ on October 16, 2026. The proposed offering comprises 9.72 million shares, priced at an indicative range of USD 17.00–19.00 each. At the indicative range midpoint, the base offering would raise approximately USD 174.96 million in gross proceeds. The reported IPO market capitalization is approximately USD 905.98 million; a separate upper valuation of $956.3 million is cited for the IPO. IPO proceeds are intended to fund clinical trials, advance the RNAi platform, and support working capital and general corporate purposes.

For the 12 months ended June 30, 2026, the company reported revenue of $14.34 million and a net loss of $87.67 million. Its lead candidate, CITY-FXI, is a GalNAc-conjugated siRNA therapeutic targeting Factor XI, in development for the prevention of thromboembolic diseases.

Goldman Sachs, Jefferies, Stifel and Oppenheimer & Co. will act as offering managers for the transaction.

Transsion (Ticker: 2636 HK) is a Chinese smart-device and mobile Internet services company focused primarily on mobile phones. Its smartphone portfolio includes TECNO, Infinix and itel, complemented by feature phones, mobile Internet services, IoT products, energy-storage products and lightweight electric-mobility products. According to Frost & Sullivan, Transsion ranked eighth in the global mobile phone market by 2025 revenue, with a 1.7% market share.

Transsion plans to list H shares on the Hong Kong Stock Exchange on October 15, 2026. The offering is expected to raise approximately $409 million and implies an estimated market capitalization of around $5.8 billion. The company manufactures products through both in-house facilities and ODM/OEM partners, with production bases in China, Bangladesh and Ethiopia, and Africa represents a major business market. BOCI Asia, CICC, CLSA, J.P. Morgan, Deutsche Bank, Daiwa Capital Markets and other banks are serving as underwriters for the offering.

Iambic Therapeutics (Ticker: IAM US) is an American clinical-stage biotechnology company headquartered in San Diego, California, and incorporated in Delaware. Founded in 2019, it combines proprietary AI models with automated chemistry and biology to develop small molecule cancer drugs.

Iambic Therapeutics is expected to list on NASDAQ on October 15, 2026, offering approximately 9.38 million shares at an indicative price range of $15.00–$17.00 per share. At the $16.00 midpoint, the IPO would raise approximately $150 million and imply an estimated market capitalization of approximately $758 million.

According to the prospectus, its lead candidate, IAM1363, is an oral, brain-penetrant HER2 inhibitor undergoing a Phase 1/1b trial for advanced HER2-altered solid tumors. A registrational trial could begin as early as 2027, subject to regulatory feedback. The company also expects to submit investigational new drug applications for IAM217 and IAM-C1 in the fourth quarter of 2026.

J.P. Morgan, Jefferies, BofA Securities and Citigroup are the joint managers.

Retension Pharmaceuticals (Ticker: RTSN US) is an American clinical-stage biotechnology company developing RTN-001, a once-daily oral treatment for uncontrolled and resistant hypertension. The company is evaluating RTN-001, its sole drug candidate, in a Phase 2b clinical trial that began in October 2025, with initial data expected in the first half of 2027.

Retension Pharmaceuticals plans to list on Nasdaq on October 9, 2026, offering 3.3 million shares at an indicated price range of $11 to $13 per share. At the $12 midpoint, the IPO would raise approximately $40 million and imply an estimated market capitalization of approximately $95 million.

The Delaware-incorporated company was founded in 2023 and reported no product revenue and a net loss of approximately $12 million for the 12 months ended June 30, 2026. Leerink Partners, Guggenheim Securities, Oppenheimer & Co. and Titan Partners are serving as joint managers for the offering.

Beijing ESWIN Computing Technology Co., Ltd. (Ticker: 1256 HK) is a Chinese semiconductor company focused on RISC-V-based chips, chipsets, circuit boards and related software for smart devices, automotive, robotics and industrial applications. The company also provides semiconductor packaging, testing and wafer-related services.

Eswin Computing plans to list on the Hong Kong Stock Exchange on October 9, 2026, offering approximately 1.57 billion primary shares at an expected price range of HKD 1.48 to HKD 1.59 per share. At the top of the range, the IPO is expected to raise approximately HKD 2.50 billion (approximately $318 million). The supplied calendar data indicates an estimated valuation of around $4.3 billion. The offering also includes a 15% greenshoe facility covering approximately 236 million shares. CLSA, CMB International Capital, China Securities International, GF Securities Hong Kong, Huatai Financial Holdings Hong Kong and other firms are among the offering managers.

TRexBio, Inc. (Ticker: TRXB US) is an American clinical-stage biotechnology company focused on tissue regulatory T-cell (Treg) biology and the development of immunoregulatory medicines for autoimmune and inflammatory diseases. The company’s Deep Biology platform is designed to identify drivers of immune dysregulation and inform drug discovery and translational development across its wholly owned pipeline and pharmaceutical collaborations. TRexBio is headquartered in South San Francisco, California.

TRexBio is expected to list on Nasdaq on October 9, 2026, following pricing on October 8. The company plans to offer approximately 8.3 million primary shares at $14.00-$16.00 per share, raising approximately $125 million at the midpoint of the proposed range. The offering is 100% primary. J.P. Morgan, Evercore, Cantor and Stifel are serving as bookrunners, with J.P. Morgan acting as stabilization agent and bill-and-deliver bank.

Sensofusion Plc (Ticker: SENSO FH) is a Finnish defense-technology company specializing in counter-drone and C-UAS systems. Its Airfence product family detects and tracks radio-frequency signals from drones and operators and supports technologies for disrupting or intercepting hostile drones.

Sensofusion expects prelist trading on Nasdaq Helsinki to begin around October 9, 2026, followed by trading on the regulated main market around October 13, 2026. The IPO price is EUR 16.41 per share.

According to published terms, the company is targeting approximately EUR 259 million from the base new-share issue and up to EUR 300 million gross, or approximately $341 million, including the over-allotment option. Including shares sold by existing shareholders, the overall offering could reach approximately EUR 317 million. The EUR 16.41 offer price implies a post-IPO valuation of approximately EUR 1.6 billion, or around $1.8 billion, assuming full completion of the share issue and over-allotment. Danske Bank is acting as manager of the offering.

Volare Shipping Ltd. (Ticker: VLCC NO) is a Singapore-domiciled shipping company focused on Very Large Crude Carriers (VLCCs). Majority-owned by Trafigura, the company operates six VLCCs and has eight newbuild vessels on order for delivery through 2028, with its fleet under Trafigura’s commercial management.

Volare Shipping plans to list on Euronext Growth Oslo on October 5, 2026, offering 30.7 million primary shares at NOK 154.00 per share. The offering is expected to raise approximately NOK 4.73 billion, equivalent to approximately $501 million. According to published terms, the offering consists entirely of primary shares and includes a 15% greenshoe facility. Clarksons Securities AS and Fearnley Securities AS are acting as managers of the offering.

Shenzhen Camsense Technologies Co., Ltd. (Ticker: 6802 HK) is a Chinese spatial sensing technology company that develops sensors, algorithms and hardware, with a focus on LiDAR and line laser products used in robotic vacuums and other robotics applications. Camsense plans to list in Hong Kong on September 30, 2026, offering approximately 11.59 million primary shares at HKD 58.85 per share.

The IPO is expected to raise approximately HKD 682 million (approximately $87 million), with a 15% greenshoe facility covering approximately 1.74 million additional shares. At the offer price, the company is valued at approximately $725 million. Camsense is offering H shares, with primary shares representing 100% of the base offering. Its products serve robotics, industrial and medical applications, and the company has also been expanding its spatial sensing technology into areas including yard robots, pool-cleaning robots and humanoid robots.

Duksan Navcours Co., Ltd. (Ticker: 266690 KS) is a South Korean aerospace and defense technology company specializing in positioning, navigation and timing (PNT) systems, including precision satellite navigation, GNSS/INS navigation and anti-jamming solutions for military, aerospace and civilian applications.

Duksan Navcours plans to list on KOSDAQ on September 30, 2026. The company priced its IPO at KRW 14,600 per share, at the top of the indicated KRW 12,400-14,600 range, offering 3 million shares and raising approximately KRW 44 billion (approximately $30 million). The offering consists entirely of primary shares. At the IPO price, Duksan Navcours has an estimated market capitalization of approximately $189 million. Daishin Securities is acting as manager of the offering. The company was founded in 2012, is headquartered in Daejeon, South Korea, and has been part of the Duksan Group since 2021.

Accelevation (Ticker: ACCV US) is a U.S.-registered infrastructure company that designs, manufactures and installs power distribution and white-space infrastructure products for mission-critical environments, serving hyperscale, colocation, AI, cloud and other large-scale data center customers.

Accelevation is expected to list on Nasdaq on September 30, 2026, following pricing after market close on September 29. The company plans to offer 30 million shares at $20.00-$24.00 per share, implying an IPO size of approximately $660 million at the midpoint and a range of $600 million-$720 million. According to the published terms, the offering consists of approximately 29% primary shares and 71% synthetic secondary shares. J.P. Morgan and Morgan Stanley are serving as bookrunners, with Morgan Stanley acting as stabilization agent and bill-and-deliver bank.

Direct Drive Tech Limited (Ticker: 6731 HK) is a Chinese robotics and precision motion-control company developing and manufacturing direct-drive motors, power modules and robotic systems.

The company plans to list on the Hong Kong Stock Exchange on September 29, 2026, offering 50.00 million primary shares at HKD 21.60 per share and raising approximately HKD 1.1 billion (approximately $138 million). The offering implies a market capitalization of approximately $1.0 billion.

Direct Drive Tech’s product portfolio includes direct-drive robotic platforms such as D1, TITA and DIABLO, as well as related motion-control technologies and robot middleware, with applications including inspection, delivery and other mobile-robotics use cases. The offering includes a 15% greenshoe facility covering 7.50 million additional shares. CLSA, CMB International Capital, China Harbour International Securities, Futu Securities International (Hong Kong) and Neutral Financial Holding are managers of the offering.

Global Technology (Ticker: 486510 KQ) is a South Korean system semiconductor company focused on display driver ICs and next-generation light-source semiconductor applications, with products and solutions targeting display, automotive electronics, communications, and Micro LED markets.

The company, headquartered in Hwaseong, Gyeonggi Province, plans to list on KOSDAQ on September 29, 2026. Global Technology is offering 4 million new shares at KRW 10,000 per share, raising KRW 40 billion, or approximately $27 million. Korea Investment & Securities is the lead manager. Based on 19.58 million shares outstanding after the offering, the IPO price implies a post-listing market capitalization of approximately KRW 196 billion, or about $134 million.

Shenzhen Kinwong Electronic Co., Ltd. (Ticker: 3228 HK) is a Chinese printed circuit board (PCB) manufacturer serving automotive electronics, telecommunications and data infrastructure, smart devices, industrial control, AI computing and other markets.

Kinwong plans to list its H shares on the Hong Kong Stock Exchange on September 29, 2026, offering approximately 72.94 million primary shares at HKD 69.88 per share and raising approximately HKD 5.1 billion (approximately $650 million). According to CIC data cited in the prospectus, the company was the world’s largest automotive electronics PCB provider by revenue in 2025, with a 10.6% market share, and ranked eleventh among PCB providers globally with a 2.5% share.

Its products include multilayer, HDI, flexible, high-layer-count and other advanced PCBs used in areas including autonomous driving, AI computing infrastructure and next-generation communications. The company served more than 800 customers across 53 countries or regions during the track record period. CLSA, Guolian Securities International Capital and Merrill Lynch Asia Pacific are managers of the offering.

Red Avenue New Materials Group Co., Ltd. (Ticker: 9607 HK) is a Chinese new materials company engaged in the R&D, production and sale of rubber additives, electronic materials and fully biodegradable materials. Red Avenue, which has been listed on the Shanghai Stock Exchange since 2018, plans to list its H shares on the Hong Kong Stock Exchange on September 29, 2026.

The company plans to offer approximately 68.12 million primary shares at HKD 39.00-44.00 per share, raising up to approximately HKD 3.0 billion (approximately $382 million). Its products include phenolic resins and other rubber additives used in tyres, semiconductor and display photoresists, CMP polishing pads, high-purity solvents and PBAT biodegradable materials.

According to Frost & Sullivan data cited in the prospectus, Red Avenue ranked first globally in phenolic resin rubber additives for tyres by 2025 sales revenue, with a 41.4% market share, and ranked first among local suppliers in China’s semiconductor and TFT-array photoresist markets. The company operates seven production facilities in China and is developing a new rubber-additives production base in Thailand.

RoboTechnik Intelligent Technology Co., Ltd. (Ticker: 3757 HK) is a Chinese provider of intelligent manufacturing equipment and systems for the photovoltaic (PV) and silicon photonics (SiPh) industries. Its offerings include PV cell automation equipment, complete production lines, intelligent manufacturing systems centered on its R2Fab MES platform, and, through ficonTEC, SiPh assembly and testing equipment.

RoboTechnik plans to list in Hong Kong on September 29, 2026, offering approximately 11.88 million primary shares at HKD 436 per share and raising approximately HKD 5.18 billion (approximately $660 million). The offering includes a 15% greenshoe facility covering approximately 1.78 million additional shares.

According to CIC data cited by the company, RoboTechnik ranked fifth globally in intelligent PV cell automation manufacturing equipment by 2025 revenue, with a 2.6% market share, and first globally in intelligent SiPh manufacturing equipment, with a 20.5% market share. Citigroup Global Markets Asia, Futu Securities International (Hong Kong), and Huatai Financial Holdings (Hong Kong) are among the offering managers.

1947 Oil & Gas PLC (Ticker: 1947 LN) is a UK-based oil and gas company focused on acquiring and operating producing assets in the United States. The company plans to list on the AIM market of the London Stock Exchange on September 28, 2026. As part of the IPO, 1947 Oil & Gas sold 297.5 million new shares to investors at 10 pence per share, raising £29.75 million, or approximately $40 million. At the offer price, the company has a market capitalization of approximately £65.1 million, or about $88 million.

In connection with the listing, the company also issues 202.5 million shares, valued at £20.25 million, to Renaissance Offshore Holdings LLC as consideration for the acquisition of Renaissance Offshore LLC, bringing the total number of new shares issued to 500 million. According to the company, net IPO proceeds and remaining pre-IPO funds will be used toward the cash consideration for the Renaissance acquisition, working capital and admission costs. Renaissance holds interests in 11 producing fields in the Gulf of Mexico.

ADARx Pharmaceuticals Inc. (Ticker: ADRX US) is a U.S. late-stage biotechnology company developing RNA-targeted therapeutics across complement-mediated, genetic, cardiovascular, thrombosis, central nervous system and metabolic diseases, including obesity. The company has developed technologies designed to selectively control the expression of disease-related targets and is advancing a pipeline of RNA therapeutic candidates. ADARx also has a collaboration and license option agreement with AbbVie covering siRNA therapeutics across multiple disease areas, including neuroscience, immunology and oncology.

ADARx plans to list on Nasdaq on September 25, 2026, following expected pricing on September 24. The company is offering 21.875 million shares at $15-$17 per share, representing an IPO size of approximately $350 million at the midpoint. The offering consists entirely of primary shares, with proceeds therefore going to the company before fees and expenses. J.P. Morgan, Morgan Stanley, TD Cowen and UBS are acting as bookrunners.

Bamboo Insurance Services (Ticker: BMB US) is a U.S. homeowners insurance business that uses technology and AI to help price policies, assess risk and manage claims. The company operates as a managing general underwriter (MGU), meaning it handles much of the insurance process while partner insurance carriers provide the capital and ultimately bear the claims risk.

Bamboo, which is incorporated in Delaware and backed by CVC, plans to list on the New York Stock Exchange on September 23, 2026. Selling shareholders are offering 35 million shares at $18.00 to $20.00 each, implying proceeds of approximately $665 million at the midpoint and up to $700 million at the top of the range. The offering implies an estimated market capitalization of around $3.0 billion, while Reuters reported a fully diluted valuation of up to approximately $3.2 billion.

All shares in the IPO are being sold by existing shareholders, so Bamboo itself will not receive any proceeds from the offering. J.P. Morgan, Morgan Stanley, Deutsche Bank Securities, Evercore ISI and Wells Fargo Securities are managing the IPO.

Ligent Technologies Inc. (Ticker: 9856 HK) is a Chinese semiconductor and optical communications company that develops products used in high-speed data networks, including optical transceivers, chips and network terminals. Its technology is designed in part for AI-driven computing networks, where large amounts of data need to move quickly between servers and data centers. The company serves customers globally.

Ligent plans to list on the Hong Kong Stock Exchange on September 22, 2026. The company is offering approximately 172.01 million new shares at HKD 32.96 per share, raising about HKD 5.67 billion, or approximately $723 million. The offering implies a market capitalization of around $4.1 billion.

All shares in the IPO are primary shares, meaning the proceeds will go to Ligent rather than existing shareholders. The offering also includes a 15% greenshoe option. CLSA, Citigroup Global Markets Asia, Futu Securities International and GF Securities Hong Kong Brokerage are among the managers of the IPO.

Transwarp (Ticker: 6727 HK) is a Chinese enterprise software company providing AI and big data infrastructure to corporate and government customers. Its software helps organizations store, manage and analyze large amounts of data, build AI applications and run cloud-based data systems. The company serves more than 1,800 customers across industries including finance, government, energy, healthcare, transportation and manufacturing, and says repeat purchases from existing customers accounted for more than 70% of revenue on average from 2023 through the first quarter of 2026.

Transwarp plans to list on the Hong Kong Stock Exchange on September 21, 2026, with an IPO raising approximately $88 million and an estimated market capitalization of about $948 million. According to Frost & Sullivan, Transwarp was China’s fifth-largest AI infrastructure software provider by revenue in 2025, with a 2.7% market share, and the country’s largest independent provider in the sector.

The company is also expanding internationally, with subsidiaries in Hong Kong, Singapore and Canada and customers in Singapore and the Middle East. BOCOM International, CMB International and several other securities firms are managing the offering.

Innovaero Technologies Ltd (Ticker: INN AU) is an Australian aerospace and defense manufacturer specializing in uncrewed aerial systems, composite aerostructures and loitering munitions, including its OWL family of precision systems. The company plans to list on the Australian Securities Exchange on September 18, 2026. Innovaero is offering 80 million primary shares at A$0.50 per share, raising A$40 million (approximately $28 million). The offering implies a market capitalization of approximately $112 million. According to published information, IPO proceeds are intended to support a new Jandakot R&D and manufacturing facility, expand sovereign drone production capacity and advance development of the OWL munitions portfolio. The offering consists entirely of primary shares. Canaccord Genuity Australia Ltd and Euroz Hartleys Ltd are managing the IPO.

Electra Therapeutics (Ticker: ETRA US) is a U.S. biotechnology company developing new medicines for immune-related diseases and cancer. Its treatments are designed to target and remove specific immune cells that contribute to disease, rather than broadly suppressing the immune system.

The company plans to list on Nasdaq on September 18, 2026. Electra priced its IPO at $15.00 per share and increased the offering to approximately 23.33 million shares, raising about $350 million. The IPO gives the company an estimated market capitalization of approximately $941 million.

Electra’s main drug candidate, ipsoprubart, is being tested in a late-stage Phase 2/3 clinical trial for secondary hemophagocytic lymphohistiocytosis (sHLH), a rare and potentially life-threatening condition involving excessive immune-system activation. The company is also developing ELA822 for immune and inflammatory diseases involving T cells.

Jefferies, TD Cowen, Evercore ISI and Cantor are managing the IPO.

Orion180 (Ticker: OIG US) is an American insurance company focused on homeowners and residential flood insurance, including excess and surplus lines coverage across 14 U.S. states. The Florida-based company plans to list on Nasdaq on September 18, 2026, with the IPO scheduled to price on September 17. Orion180 plans to offer 20 million shares at $15–$17 each, raising up to approximately $340 million and implying a valuation of around $1.7 billion.

Founded in 2018 by Kenneth Gregg, the company’s key markets include Texas, California and Florida. Orion180 generated approximately $601 million of managed premiums written during the 12 months ended June 30, 2026. RBC Capital Markets, UBS Investment Bank and Raymond James are serving as lead book-running managers for the offering.

Oliver Corporation (Ticker: 619A JP) is a Japanese commercial services company providing end-to-end interior solutions, spanning planning, design, consulting, project management, furniture manufacturing and interior construction. The company serves offices, hotels, restaurants, retail locations, healthcare facilities and other commercial and public spaces, supported by more than 100 designers. Oliver plans to list on the Tokyo Stock Exchange Standard Market on September 16, 2026.

The IPO was priced at JPY 305 per share, at the top of the JPY 295-305 range. The offering comprises approximately 74.1 million shares, raising approximately JPY 22.6 billion (approximately $142 million), before a potential 11.1 million-share overallotment. The offering consists entirely of secondary shares, with no primary shares being issued, meaning the proceeds from the base offering will go to selling shareholders rather than the company. The implied market capitalization at the offer price is approximately JPY 30.5 billion, or around $191 million.

Oliver’s largest shareholders include private equity-related entities Integral No. 4 Investment Limited Partnership, Initiative Delta IV L.P., Innovation Alpha IV L.P. and Integral Corporation. Daiwa Securities and Nomura Securities are the lead managers of the offering.

KOMPEITO Inc. (Ticker: 618A JP) is a Japanese food services company focused on workplace food and employee welfare solutions. Its core “OFFICE DE YASAI” service provides healthy meals, including salads and boxed meals, through refrigerators and freezers installed in offices. The company also operates in the United States through subsidiaries including KOMPEITO USA Inc.

KOMPEITO plans to list on the Tokyo Stock Exchange Growth Market on September 11, 2026. The IPO was priced at JPY 1,600 per share, at the top of the JPY 1,560-1,600 range. The offering comprises approximately 4.19 million shares, raising approximately JPY 6.70 billion (approximately $42 million), before a potential 628,200-share overallotment. Approximately 98.8% of the offering consists of secondary shares, with only 50,000 primary shares issued by the company. The implied market capitalization at the offer price is approximately JPY 15.84 billion, or around $99 million. SBI Securities is the lead manager.

Shenzhen Longsys Electronics Co., Ltd. (Ticker: 9976 HK) is a Chinese semiconductor memory products company that designs, develops, back-end manufactures and sells storage and memory products for consumer, enterprise and industrial applications. The company operates the FORESEE, Zilia and Lexar brands and does not manufacture memory wafers, instead sourcing wafers and controller chips from third-party suppliers.

Shenzhen Longsys plans to list on the Hong Kong Stock Exchange on September 8, 2026. The IPO is priced at HKD 236.00 per share, below the indicated HKD 240.60 range, with approximately 26.08 million shares offered. The base offering is expected to raise approximately HKD 6.15 billion, or approximately $785 million. All shares in the base offering are primary shares, with a 15% greenshoe covering approximately 3.91 million additional shares.

The offering is being managed by firms including ABCI Capital, CLSA, China Securities International, Citigroup Global Markets Asia and Futu Securities International.